PRODUCT PORTFOLIO
PCSK9 inhibitor Evidence-based Long-standing heritage therapies, intuitive in insulin innovation diagnostics and easy-to-use pens
Combination therapy
*
Patient-friendly delivery pens Intelligent blood glucose monitoring systems Once-daily, prandial GLP-1 receptor agonist
Solid base in oral anti-diabetic treatments
Long-standing heritage in insulin innovation
Product About the product
Toujeo® (insulin glargine 300 Units/mL) is a once-daily basal insulin, that is Toujeo® available in more than 60 countries. Toujeo® is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.1
Lantus® (insulin glargine 100 Units/mL) is a long-acting basal insulin analog that provides a slow, steady release of insulin and helps manage blood sugar between meals, and overnight.2 Lantus® The cornerstone of Sanofi’s diabetes portfolio, Lantus has helped more than 10 million people with diabetes over 89 million patient-years since launch, in more than 130 countries.
Insuman® (human insulin 100 IU/mL) includes a range of rapid and intermediate Insuman® human insulin solutions and suspensions for injections. Insuman is used in patients with diabetes who need treatment with insulin.3,4
Apidra® (insulin glulisine injection) is an add-on to basal insulin in ® basal-bolus regimen. Apidra is indicated for the treatment of adults, Apidra adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required.5
Long-standingOnce-daily prandial heritage GLP-1 in insulinreceptor innovation agonist
Product About
Lyxumia® (lixisenatide) is a once-daily mealtime (prandial) GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus. Lyxumia® is approved in more than 60 countries worldwide, and lixisenatide is also Lyxumia® approved as Adlyxin® (lixisenatide) in the U.S.†6,7 Lyxumia® aims to achieve glycemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control.6,7
Long-standingCombination heritage in therapy insulin innovation
Product About
Soliqua® is a once-daily titratable fixed-ratio combination of insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. It is approved in the U.S. as Soliqua® 100/33 and in the EU as Suliqua®.8,9 Soliqua® Soliqua® combines two widely-used medicines with complementary modes of action addressing both fasting plasma glucose (FPG) and post-prandial glucose (PPG). This is particularly relevant for people whose type 2 diabetes is uncontrolled, despite using basal insulin.8,9
Long-standing PCSK9heritage inhibitor in insulin innovation
Product About
Praluent® (alirocumab) is a PCSK9 inhibitor for the treatment of people who have raised levels of ‘bad’ cholesterol (low-density lipoprotein cholesterol, or LDL-C).10 ® Praluent® Praluent is used along with diet and the highest tolerated dose of a statin in adults with heterozygous familial (an inherited condition that causes high levels of LDL cholesterol) and non-familial hypercholesterolemia or mixed dyslipidemia who need additional lowering of LDL cholesterol.10
Long-standingSolid base in oralheritage anti-diabetic in insulin treatments innovation
Product About
Amaryl® (glimepiride) is an oral blood glucose-lowering drug of the sulfonylurea Amaryl® class. Amaryl is indicated for the treatment of type 2 diabetes mellitus, when diet, physical exercise and weight reduction alone are not adequate.11
Daonil® (glibenclamide) is an oral blood glucose-lowering drug of the ® ® sulfonylurea class. Daonil is a sulphonylurea hypoglycemic agent, indicated Daonil for the oral treatment of patients with non-insulin dependent diabetes who respond inadequately to dietary measures alone.12
Patient-friendly delivery pens‡
Product About
ALLSTAR™ is a high-quality pen for use with Lantus, designed for ALLSTAR™ emerging markets.
® ® ® ® SoloStar and ClikStar are Sanofi’s two award-winning delivery devices SoloStar /ClikStar providing high patient satisfaction.
JuniorStar® is an award-winning, half-unit, reusable pen specifically ® designed for young people with type 1 diabetes by being lightweight JuniorStar and easy-to-use with its large dose display, single-step dial back and easily replaceable cartridges.
® ® The award-winning Lyxumia pens have been recognized for design Lyxumia pens in Europe, North America and Japan and come with pre-set doses.
® ® ® ® The Soliqua award-winning SoloStar pens are pre-filled, disposable Soliqua SoloStar pens and available in two different strengths.
® ® ® ® The Toujeo pen is available as a re-designed, pre-filled SoloStar pen, Toujeo SoloStar pen and has an award-winning design.
The new Max SoloStar® pen holds 900 Units of Toujeo®, more than any other Toujeo® Max SoloStar® long-acting insulin pen in the U.S., and provides up to 160 Units/mL of Toujeo® in a single injection. Toujeo® Max SoloStar® is only authorized in the U.S.
Intelligent blood glucose monitoring system
The MyStar® Portfolio MyStar® is an integrated portfolio for simpler and more effective diabetes management. The portfolio includes medical devices, solutions and guidance and when combined with our drug offering, aims to meet patients’ needs holistically.
Product About Product About
MyStar Connect® is comprehensive data management software that optimizes diabetes BGStar® is an easy-to-use, accurate and reliable MyStar therapy. It provides healthcare professionals blood glucose monitoring device, designed (HCPs) with the necessary insights and analysis ® with specific features to help minimize errors ® BGStar Connect to identify key areas needing attention, and thus and improve confidence in daily glucose supports their clinical decision-making for each management. individual patient.
MyStar Extra® is the first blood glucose MyStar DoseCoach® is an insulin glargine dose
meter that provides an estimated HbA1C value. helper and integrated blood glucose meter in MyStar It is designed to keep people with diabetes MyStar one single device. MyStar DoseCoach® helps Extra® motivated in their diabetes management DoseCoach® people with type 2 diabetes on basal therapy to and engaged to track their therapy progress self-adjust their insulin glargine dose in between – even between doctor visits. visits, according to criteria selected by their HCPs.
MyStar Plus® is an advanced blood glucose MyStar monitoring system that sends blood glucose data to the MyStar Plus® App using Bluetooth ® Plus wireless technology, helping patients manage their diabetes around their lifestyle.**
*Suliqua® is the brand name in the EU. Within the U.S. it is branded as Soliqua® 100/33 †Lyxumia was in-licensed from Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), http://www.zealandpharma.com. Lyxumia was approved in Europe in 2013 and is currently approved in over 60 countries worldwide for the treatment of adults with type 2 diabetes, with commercial launches in Europe, Japan, Mexico and other markets. Lyxumia is the proprietary name approved by the European Medicines Agency and other health authorities for the GLP-1 RA lixisenatide.[Date accessed: June 2017]. ‡ClikStar, AllStar and JuniorStar pens are reusable; SoloStar and Lyxumia pens are disposable. **MyStar Plus: App is compatible with GooglePlay and Apple. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Sanofi is under license. Other trademarks and trade names are those of their respective owners. For more information on all products, please consult the Product Information in your country. Not all products and programs are available in all countries.
REFERENCES:
1 . Toujeo SmPC Feb 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf [Date accessed: June 2018]. 2 . Lantus SmPC Jul 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf [Date accessed: June 2018]. 3 . Insuman SmPC Mar 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000201/WC500033784.pdf [Date accessed: June 2018]. 4 . EMA data on Insuman. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Supply_shortage/2015/03/WC500185164.pdf [Date accessed: June 2018]. 5 . Apidra SmPC Jul 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000557/WC500025250.pdf [Date accessed: June 2018]. 6 . Lyxumia SmPC Oct 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf [Date accessed: June 2018]. 7 . Adlyxin PI Jul 2016. Available at: http://products.sanofi.us/adlyxin/adlyxin.pdf [Date accessed: June 2018]. 8 . Soliqua 100–33 PI Oct 2017. Available at: http://products.sanofi.us/Soliqua100-33/Soliqua100-33.pdf [Date accessed: June 2018]. 9 . Suliqua SmPC Oct 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004243/WC500224673.pdf [Date accessed: June 2018]. 10. Praluent SmPC Jan 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003882/WC500194521.pdf [Date accessed: June 2018]. 11. Amaryl SmPC Apr 2017. Available at: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1518153414731.pdf [Date accessed: June 2018]. 12. Glibenclamide SmPC Sep 2015. Available at: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1513315161827.pdf [Date accessed: June 2018].
For medical journalists outside the U.S. only